Nomura Hires Senior Analyst for Biotech in U.S. Equity Research

Mr. Marai will be based in San Francisco and joins Nomura from Oppenheimer & Co., where he was most recently a Managing Director and top-ranked senior analyst covering the Biotechnology sector. He previously worked at Wedbush Securities PacGrow Life Sciences with a particular focus on rare diseases, oncology and infectious disease.

“We are committed to strategically expanding our equity research coverage in the Americas,” said Penn Egbert, Head of Global Markets Research for Nomura in the Americas. “Christopher is a tremendous addition to our platform. His hire allows us to expand our coverage footprint and enables Nomura to provide highly actionable ideas and investment services to a wider range of clients.”

Nomura is recognized for its commitment to research in Japan and the firm consistently achieves top rankings for Japanese equity research, placing #2 in Institutional Investor’s 2016 All-Japan Research Survey. In addition to equity research, Nomura offers leading fixed income, economic and quantitative research in the Americas.

On June 15, 2016, it was announced that Instinet will integrate Nomura’s U.S. Equity Research and U.S. research sales services into its agency brokerage platform in the Americas. U.S. equity research and U.S. research sales personnel currently servicing clients from Nomura Securities International, Inc., will transfer to Instinet, LLC, upon regulatory approval.

The new organizational structure will present clients with a focused, boutique-style content offering that is tightly paired with Instinet’s deep liquidity and diverse execution capabilities currently provided to more than 1,000 clients. Following the transition, clients will continue to have seamless access to both Nomura and Instinet’s research offerings globally.